LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Sanofi

Sanofi

Cerrado

42.7 -0.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

42.68

Máximo

43.2

Métricas clave
By Trading Economics
Ingresos	2.4B 1.6B
Ventas	-961M 11B
P/B Media del Sector	18.24 51.415
BPA	1.102
Margen de beneficios	14.354
Empleados	74,846
EBITDA	-1.1B 2.7B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+23.69% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-13B 102B
Apertura anterior	43.03
Cierre anterior	42.7

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

51.665 / 52.38 Soporte y Resistencia

Sanofi Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2026, 06:12 UTC

Ganancias

Sanofi Posts Higher Sales Amid Leadership Transition

12 feb 2026, 12:40 UTC

Principales Movimientos del Mercado

Sanofi Shares Fall After CEO Change

7 may 2026, 06:47 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

29 abr 2026, 12:01 UTC

Ganancias

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 abr 2026, 09:32 UTC

Charlas de Mercado

Ganancias

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 abr 2026, 09:19 UTC

Charlas de Mercado

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 abr 2026, 05:34 UTC

Ganancias

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 abr 2026, 05:34 UTC

Ganancias

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 abr 2026, 05:34 UTC

Ganancias

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 abr 2026, 05:34 UTC

Ganancias

Sanofi Backs 2026 View

23 abr 2026, 05:33 UTC

Ganancias

Sanofi 1Q Business Net Pft EUR2.26B

23 abr 2026, 05:33 UTC

Ganancias

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 abr 2026, 05:33 UTC

Ganancias

Sanofi 1Q Business Oper Pft EUR2.97B

23 abr 2026, 05:32 UTC

Ganancias

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 abr 2026, 05:32 UTC

Ganancias

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 abr 2026, 05:31 UTC

Ganancias

Sanofi 1Q Net Sales EUR10.51B

10 abr 2026, 11:12 UTC

Charlas de Mercado

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 abr 2026, 10:54 UTC

Charlas de Mercado

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 mar 2026, 10:40 UTC

Charlas de Mercado

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 mar 2026, 10:40 UTC

Charlas de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 mar 2026, 11:02 UTC

Charlas de Mercado

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 feb 2026, 14:00 UTC

Adquisiciones, fusiones, absorciones

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 feb 2026, 08:21 UTC

Charlas de Mercado

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 feb 2026, 15:20 UTC

Ganancias

Sanofi Shares Fall After CEO Change -- Update

10 feb 2026, 14:07 UTC

Adquisiciones, fusiones, absorciones

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 feb 2026, 14:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 feb 2026, 14:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes Acquisition of Dynavax

10 feb 2026, 14:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 feb 2026, 12:35 UTC

Ganancias

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 ene 2026, 13:00 UTC

Charlas de Mercado

Ganancias

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Comparación entre iguales

Cambio de precio

Sanofi previsión

Precio Objetivo

By TipRanks

23.69% repunte

Estimación a 12 Meses

Media 53 USD 23.69%

Máximo 57 USD

Mínimo 50 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Sanofi Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

51.665 / 52.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.